News
Steroid May Reduce COVID-19 Death Risk by Up to One-Third
Dexamethasone appears promising for patients with severe illness.
Your search for supplemental oxygen returned 75 results
Drugs in the Pipeline
Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
News
Five-Day Course of Remdesivir Beneficial in Severe COVID-19
No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.
Drugs in the Pipeline
Intravenous Choline Chloride Fast-Tracked for Intestinal Failure-Associated Liver Disease
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
News
Remdesivir Improves Time To Recovery for Patients Hospitalized With COVID-19
Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.
Drugs in the Pipeline
High Dose IVIG to Be Investigated for Severe COVID-19 in Phase 3 Trial
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Drugs in the Pipeline
Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
News
At-Home Use of Inhaled Nitric Oxide for Pulmonary HTN Complicated by COVID-19
Treatment with inhaled nitric oxide has been shown to have both pulmonary and antiviral benefits.
ATS 2020
Inhaled Nitric Oxide at Higher Dose Improves Activity in PH Associated With ILD
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
News
INOpulse Inhaled Nitric Oxide to Be Assessed for COVID-19 in Phase 3 Study
The Food and Drug Administration has cleared the initiation of a phase 3 trial evaluating INOpulse® inhaled nitric oxide (iNO) therapy (Bellerophon Therapeutics) in patients with coronavirus disease 2019 (COVID-19).
